Code
MOG-BTKX-03BZ
Panel
Active-Compendium
81233, 81320
81479
Clinical
Oncology,Pathology
<p><b>Bone Marrow Aspirate:</b> 2 mL in EDTA tube.<br>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.</p>
<b>Peripheral Blood:</b> 5 mL in EDTA tube.<br>
<b>Note:</b> Test is DNA-based. Please select Extract & Hold - DNA if specimen hold service is desired.</p>
Flag Active
True
Orderable Test Description
This test uses bi-directional sequencing of hotspot regions in BTK and PLC-gamma-2 genes, including the BTK mutation C481S and key PLC-gamma-2 mutations: R665W, S707, and L845F.
Orderable Turn Around Time
10 Days
Keywords
NY Approved
False
Orderable Biomarkers JSON
{"DNA Sequencing": {"SNVs + Indels": ["BTK", "PLCG2"]}}
Keywords string
BTK, BTK Inhibitor, BTK Inhibitor Resistance, ibrutinib, CLL, bruton tyrosine kinase, PLC-gamma-2, acquired resistance BTK Inhibitor Acquired Resistance Panel
Title URL
btk-inhibitor-acquired-resistance-panel
Clinical Significance
This panel detects mutations in BTK and PLC-gamma-2 which are associated with acquired ibrutinib resistance in certain B-cell neoplasms. This panel is appropriate for patients with B-cell neoplasms who have relapsed and/or show acquired (secondary) resistance after an initial response to BTK (Bruton tyrosine kinase) inhibitors.
Storage and transportation
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. For fresh samples: refrigerate before shipping and ship same day as drawn whenever possible. Do not freeze. Please select extract & hold - DNA if specimen hold service is desired.